Clinical Trial Update: Intravenously Administered M6229 in Critically Ill Sepsis Patients [Phase 1]

View source ↗

Summary

Phase 1 trial of intravenously administered M6229 in patients with sepsis and septic shock has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• M6229 (M6229)

Snippet

Sponsor: A.P.J. Vlaar | Conditions: Sepsis, Septic Shock | Phase 1 | Status: COMPLETED